However, to meet these
targets, the traditional approach of broad, population - based
treatments, prevention messages, and technologies must give way to more specific and focused approaches, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of
Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleague Hilary D. Marston, M.D., M.P.H.
Researchers at the La Jolla Institute for
Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug
target for the
treatment of rheumatoid arthritis that focuses on the cells that are directly responsible for the cartilage damage in affected joints.